Literature DB >> 28612307

Atypical subtrochanteric fractures in Korean hip fracture study.

Y-K Lee1, T-Y Kim2, Y-C Ha3, S-H Song4, J W Kim5, H C Shon6, J S Chang7, K-H Koo8.   

Abstract

In Korean, atypical subtrochanteric fractures (ASF) were rare. Higher BMI and use of bisphosphonate were significant risk factors of ASF.
INTRODUCTION: Recently, ASF have been reported to increase among patients on bisphosphonate. However, the incidence of ASF and the association between ASF and bisphosphonate use have not been well defined in Asian population. Our purposes are (1) to estimate the proportion of ASF among Korean patients with proximal femur fracture and (2) to determine the associated risk factors of ASF in the Korean patients.
METHODS: We conducted a multicenter (16 academic hospitals), prospective Korean hip fracture study on hip fracture in a cohort of patients aged 50 years or older from South Korea between July 2014 and May 2016. As a part of Korean hip fracture study, primary analysis examined the proportion of ASF among proximal femur fracture. To identify ASF, according to the definition by ASBMR task force, all radiographs of subtrochanteric fracture were reviewed. Associated risk factors for occurrence of ASF were also evaluated by using multivariable logistic regression analysis.
RESULTS: Among 1361 patients with proximal femoral fractures due to low-energy trauma, 17 fractures (1.2%) were identified as ASF. Higher BMI and use of bisphosphonate before injury were independent risk factors of ASF.
CONCLUSION: In Korean, ASF were rare. Higher BMI and use of bisphosphonate were significant risk factors of ASF.

Entities:  

Keywords:  Atypical subtrochanteric fracture; Bisphosphonate; East Asian

Mesh:

Substances:

Year:  2017        PMID: 28612307     DOI: 10.1007/s00198-017-4112-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  26 in total

1.  Functional outcome after hip fracture. Effect of general versus regional anesthesia.

Authors:  K J Koval; G B Aharonoff; A D Rosenberg; R L Bernstein; J D Zuckerman
Journal:  Clin Orthop Relat Res       Date:  1998-03       Impact factor: 4.176

2.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

Authors:  M E Charlson; P Pompei; K L Ales; C R MacKenzie
Journal:  J Chronic Dis       Date:  1987

3.  Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features.

Authors:  Andrea Giusti; Neveen A T Hamdy; Olaf M Dekkers; Sharita R Ramautar; Sander Dijkstra; Socrates E Papapoulos
Journal:  Bone       Date:  2010-12-31       Impact factor: 4.398

4.  Bisphosphonate use and atypical fractures of the femoral shaft.

Authors:  Jörg Schilcher; Karl Michaëlsson; Per Aspenberg
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

5.  Factors associated with atypical femoral fracture.

Authors:  Dam Kim; Yoon-Kyoung Sung; Soo-Kyung Cho; Minkyung Han; Yee-Suk Kim
Journal:  Rheumatol Int       Date:  2015-07-23       Impact factor: 2.631

Review 6.  Disentangling the emerging evidence around atypical fractures.

Authors:  Bo Abrahamsen; Emma M Clark
Journal:  Curr Rheumatol Rep       Date:  2012-06       Impact factor: 4.592

7.  Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate.

Authors:  Jörg Schilcher; Per Aspenberg
Journal:  Acta Orthop       Date:  2009-08       Impact factor: 3.717

Review 8.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

9.  Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  J Bone Miner Res       Date:  2009-06       Impact factor: 6.741

Review 10.  Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.

Authors:  R Rizzoli; K Akesson; M Bouxsein; J A Kanis; N Napoli; S Papapoulos; J-Y Reginster; C Cooper
Journal:  Osteoporos Int       Date:  2010-11-18       Impact factor: 4.507

View more
  4 in total

1.  CORR Insights®: Postoperative Thromboprophylaxis With New Oral Anticoagulants is Superior to LMWH in Hip Arthroplasty Surgery: Findings from the Swedish Registry.

Authors:  Kyung-Hoi Koo
Journal:  Clin Orthop Relat Res       Date:  2019-06       Impact factor: 4.176

Review 2.  Evaluation and management of atypical femoral fractures: an update of current knowledge.

Authors:  O Pearce; T Edwards; K Al-Hourani; M Kelly; A Riddick
Journal:  Eur J Orthop Surg Traumatol       Date:  2021-02-15

3.  Evaluation of the Nature and Etiologies of Risk Factors for Diaphyseal Atypical Femoral Fractures.

Authors:  Hiroyuki Tsuchie; Naohisa Miyakoshi; Yuji Kasukawa; Koji Nozaka; Kimio Saito; Hayato Kinoshita; Moto Kobayashi; Norio Suzuki; Toshiaki Aizawa; Hidekazu Abe; Shigeto Maekawa; Takenori Tomite; Yuichi Ono; Kentaro Ouchi; Nobusuke Shibata; Itsuki Nagahata; Masaaki Takeshima; Manabu Akagawa; Yusuke Yuasa; Chie Sato; Yoichi Shimada
Journal:  Med Princ Pract       Date:  2021-05-31       Impact factor: 1.927

4.  The Genetics of Atypical Femur Fractures-a Systematic Review.

Authors:  Wei Zhou; Jeroen G J van Rooij; Peter R Ebeling; Annemieke J M H Verkerk; M Carola Zillikens
Journal:  Curr Osteoporos Rep       Date:  2021-02-15       Impact factor: 5.096

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.